The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature

Cancer Letters

Volumn 326, Issue 2, 2012, Pages 161-167

  Oliveira Ferrer, Leticia ^a   Wellbrock, Jasmin ^a   Braig, Melanie ^a   Klokow, Marianne ^a   Hauschild, Jessica ^a   Bokemeyer, Carsten ^a   Fiedler, Walter ^a   Ergun, Suleyman ^b   Schuch, Gunter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

3 Hydroxiglutaric acid (3 OH GA); Angiogenesis; D53; Glioblastoma; Glutaric aciduria type I (GAI); VE Cadherin

Indexed keywords

3 HYDROXYGLTUARIC ACID; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; MATRIGEL; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM; GENE TARGETING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; MULTINUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR VASCULARIZATION;

ANIMALS; BLOOD VESSELS; CELL DIVISION; CELL LINE, TUMOR; DNA, COMPLEMENTARY; GLIOBLASTOMA; GLUTARATES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84866870671     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.002     Document Type: Article

References (17)

1. Das A.M., Lucke T., Ullrich K. Glutaric aciduria I: creatine supplementation restores creatinephosphate levels in mixed cortex cells from rat incubated with 3-hydroxyglutarate. Mol. Genet. Metab. 2003, 78:108-111.
2. Ullrich K., Flott-Rahmel B., Schluff P., Musshoff U., Das A., Lucke T., Steinfeld R., Christensen E., Jakobs C., Ludolph A., Neu A., Roper R. Glutaric aciduria type I: pathomechanisms of neurodegeneration. J. Inherit. Metab. Dis. 1999, 22:392-403.
3. Muhlhausen C., Ott N., Chalajour F., Tilki D., Freudenberg F., Shahhossini M., Thiem J., Ullrich K., Braulke T., Ergun S. Endothelial effects of 3-hydroxyglutaric acid: implications for glutaric aciduria type I. Pediatr. Res. 2006, 59:196-202.
4. Parker B.S., Argani P., Cook B.P., Liangfeng H., Chartrand S.D., Zhang M., Saha S., Bardelli A., Jiang Y., St.Martin T.B., Nacht M., Teicher B.A., Klinger K.W., Sukumar S., Madden S.L. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res. 2004, 64:7857-7866.
5. Shih S.C., Robinson G.S., Perruzzi C.A., Calvo A., Desai K., Green J.E., Ali I.U., Smith L.E., Senger D.R. Molecular profiling of angiogenesis markers. Am. J. Pathol. 2002, 161:35-41.
6. Goldbrunner R.H., Bendszus M., Wood J., Kiderlen M., Sasaki M., Tonn J.C. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004, 55:426-432.
7. Szentirmai O., Baker C.H., Bullain S.S., Lin N., Takahashi M., Folkman J., Mulligan R.C., Carter B.S. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. J. Neurosurg. 2008, 108:979-988.
8. Anderson J.C., McFarland B.C., Gladson C.L. New molecular targets in angiogenic vessels of glioblastoma tumours. Expert. Rev. Mol. Med. 2008, 10:e23.
9. Westphal M., Haensel M., Mueller D., Laas R., Kunzmann R., Rohde E., Koenig A., Hoelzel F., Herrmann H.D. Biological and karyotypic characterization of a new cell line derived from human gliosarcoma. Cancer Res. 1988, 48:731-740.
10. Westphal M., Hansel M., Hamel W., Kunzmann R., Holzel F. Karyotype analyses of 20 human glioma cell lines. Acta Neurochir. (Wien.) 1994, 126:17-26.
11. Mariani T.J., Budhraja V., Mecham B.H., Gu C.C., Watson M.A., Sadovsky Y. A variable fold change threshold determines significance for expression microarrays. FASEB J. 2003, 17:321-323.
12. Boutros R., Byrne J.A. D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Exp. Cell Res. 2005, 310:152-165.
13. Carmeliet P., Lampugnani M.G., Moons L., Breviario F., Compernolle V., Bono F., Balconi G., Spagnuolo R., Oosthuyse B., Dewerchin M., Zanetti A., Angellilo A., Mattot V., Nuyens D., Lutgens E., Clotman F., de Ruiter M.C., Gittenberger-de G.A., Poelmann R., Lupu F., Herbert J.M., Collen D., Dejana E. Targeted deficiency or cytosolic truncation of the VE-Cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999, 98:147-157.
14. Crosby C.V., Fleming P.A., Argraves W.S., Corada M., Zanetta L., Dejana E., Drake C.J. VE-Cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood 2005, 105:2771-2776.
15. Barbaric D., Byth K., la-Pozza L., Byrne J.A. Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations. Leuk. Res. 2006, 30:1355-1363.
16. Goodman S.I., Frerman F.E. Organic acidemias due to defects in lysine oxidation: 2-ketoadipic acidemia and glutaric acidemia. The Metabolic and Molecular Bases of Inherited Disease 2001, 2195-2204. McGraw-Hill Inc, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler, B. Vogelstein (Eds.).
17. Oliveira-Ferrer L., Hauschild J., Fiedler W., Bokemeyer C., Nippgen J., Celik I., Schuch G. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J. Exp. Clin. Cancer Res. 2008, 27:86.